Alliance For Clinical Trials In Oncology Foundation
Alliance For Clinical Trials In Oncology Foundation maintains strong financial health with growing assets and no reported officer compensation.
EIN: 20464400 · Chicago, IL · NTEE: H31Z · Updated: 2026-03-28
| Metric | Value |
|---|---|
| Total Revenue | $68.0M |
| Total Expenses | $40.0M |
| Program Spending | 90% |
| CEO/Top Officer Pay | $40 |
| Net Assets | $43.0M |
| Transparency Score | 90/100 |
Is Alliance For Clinical Trials In Oncology Foundation Legit?
Some Concerns
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
Alliance For Clinical Trials In Oncology Foundation directs 90% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Alliance For Clinical Trials In Oncology Foundation
Alliance For Clinical Trials In Oncology Foundation (EIN: 20464400) is a nonprofit organization based in Chicago, IL, classified under NTEE code H31Z. The organization reported total revenue of $68.0M and total assets of $112.8M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Alliance For Clinical Trials In Oncology Foundation's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Alliance For Clinical Trials In Oncology Foundation is a major nonprofit that has been operating for 32 years, with 13 years of IRS 990 filings on record (2011–2023). Revenue has grown at a compound annual rate of 8.0%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $41.5M |
| Total Expenses | $40.0M |
| Surplus / Deficit | +$1.5M |
| Total Assets | $118.1M |
| Total Liabilities | $75.1M |
| Net Assets | $43.0M |
| Operating Margin | 3.6% |
| Debt-to-Asset Ratio | 63.6% |
| Months of Reserves | 35.4 months |
Financial Health Grade: A
In 2023, Alliance For Clinical Trials In Oncology Foundation reported a surplus of $1.5M with revenue exceeding expenses, holds 35.4 months of operating reserves (strong position), has a debt-to-asset ratio of 63.6% (high leverage).
Financial Trends
Over 13 years of filings (2011–2023), Alliance For Clinical Trials In Oncology Foundation's revenue has grown at a compound annual growth rate (CAGR) of 8.0%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | +5.4% | -6.7% | -2.9% |
| 2022 | -1.4% | +6.4% | +1.7% |
| 2021 | -2.4% | +8.7% | +21.5% |
| 2020 | -19.4% | -21.0% | -3.2% |
| 2019 | -15.6% | -8.9% | -10.7% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 1000 |
| IRS Ruling Date | 1994 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Alliance For Clinical Trials In Oncology Foundation with a Mission Score of 90 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 5%
- programs: 90%
- fundraising: 5%
According to IRS 990 filings, Alliance For Clinical Trials In Oncology Foundation allocates its expenses as follows: admin: 5%, programs: 90%, fundraising: 5%. With 90% directed toward programs, this reflects a strong commitment to its charitable mission.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a surplus of $1.5M, with revenue exceeding expenses.
- Debt-to-asset ratio: 63.6%.
Executive Compensation Analysis
The organization consistently reports 0% officer compensation across all available filings, which is highly unusual for an organization of its size with revenues often exceeding $40 million. This suggests that executive leadership may be compensated through other mechanisms not classified as officer compensation on the 990, or they are entirely volunteer-based, which would be exceptional.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of Alliance For Clinical Trials In Oncology Foundation's IRS 990 filings:
- Consistent 0% officer compensation for a large organization, which warrants further investigation into how leadership is compensated or supported.
Strengths
The following positive indicators were identified for Alliance For Clinical Trials In Oncology Foundation:
- Strong and consistent asset growth, from $53.8M in 2014 to $118.1M in 2023.
- Revenues consistently exceed expenses in most years, indicating financial health (e.g., $41.5M revenue vs. $40.0M expenses in 2023).
- No reported officer compensation across all filings, suggesting a highly efficient or volunteer-driven leadership structure.
- Consistent filing history (13 filings) demonstrates good transparency and compliance.
Frequently Asked Questions about Alliance For Clinical Trials In Oncology Foundation
Is Alliance For Clinical Trials In Oncology Foundation a legitimate charity?
Alliance For Clinical Trials In Oncology Foundation (EIN: 20464400) is a registered tax-exempt nonprofit based in Illinois. Our AI analysis gives it a Mission Score of 90/100. It has 13 years of IRS 990 filings on record. Total revenue: $68.0M. 1 red flag identified. 4 strengths noted. Financial health grade: A.
How does Alliance For Clinical Trials In Oncology Foundation spend its money?
Alliance For Clinical Trials In Oncology Foundation directs 90% of its spending to programs and services. Fundraising costs 5%. This exceeds the 65% industry benchmark.
Are donations to Alliance For Clinical Trials In Oncology Foundation tax-deductible?
Alliance For Clinical Trials In Oncology Foundation is registered as a tax-exempt nonprofit (EIN: 20464400). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
How much does the Alliance For Clinical Trials In Oncology Foundation CEO make?
Alliance For Clinical Trials In Oncology Foundation's highest-compensated officer earns $40 annually. The organization reported $68.0M in total revenue. Executive compensation data is disclosed in IRS 990 filings.
What percentage of Alliance For Clinical Trials In Oncology Foundation's spending goes to programs?
Alliance For Clinical Trials In Oncology Foundation directs 90% to programs, 5% to fundraising. This exceeds the 65% industry benchmark for efficient nonprofits.
How does Alliance For Clinical Trials In Oncology Foundation compare to similar nonprofits?
With a transparency score of 90/100 (Excellent), Alliance For Clinical Trials In Oncology Foundation is above average for NTEE category H31Z nonprofits. The score reflects financial transparency, program spending efficiency, and governance quality based on IRS 990 data.
Where is Alliance For Clinical Trials In Oncology Foundation located?
Alliance For Clinical Trials In Oncology Foundation is headquartered in Chicago, Illinois and files with the IRS under EIN 20464400. It is classified under NTEE code H31Z.
How many years of IRS 990 filings does Alliance For Clinical Trials In Oncology Foundation have?
Alliance For Clinical Trials In Oncology Foundation has 13 years of IRS 990 filings on record at NonprofitSpending. This extensive filing history provides a strong basis for evaluating long-term financial trends. The most recent filing shows $68.0M in total revenue.
Is Alliance For Clinical Trials In Oncology Foundation a good charity?
Based on the provided financial data, the Alliance For Clinical Trials In Oncology Foundation appears to be a financially sound organization with consistent revenue generation, growing assets, and a notable absence of reported officer compensation, suggesting strong financial stewardship and a focus on its mission.
How does the organization manage to report 0% officer compensation?
The consistent reporting of 0% officer compensation is highly unusual for an organization of this scale. It could indicate that executive leadership is compensated through a related entity, receives no compensation, or that compensation is categorized differently within the 990, such as under program or administrative expenses, rather than specifically as officer compensation.
What is the trend in the organization's financial stability?
The organization demonstrates strong financial stability. Assets have more than doubled from $53.8 million in 2014 to $118.1 million in 2023, and revenues have consistently exceeded expenses in most years, indicating healthy financial management and growth.
Filing History
IRS 990 filing history for Alliance For Clinical Trials In Oncology Foundation showing financial trends over 13 years of public records:
Over 13 years of IRS 990 filings (2011–2023), Alliance For Clinical Trials In Oncology Foundation's revenue has grown by 152.4%, moving from $16.4M to $41.5M. Total assets increased by 199.9% over the same period, from $39.4M to $118.1M. Total functional expenses rose by 219.4%, from $12.5M to $40.0M. In its most recent filing year (2023), Alliance For Clinical Trials In Oncology Foundation reported a surplus of $1.5M, with revenue exceeding expenses. The organization holds $75.1M in liabilities against $118.1M in assets (debt-to-asset ratio: 63.6%), resulting in net assets of $43.0M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $41.5M | $40.0M | $118.1M | $75.1M | — | — |
| 2022 | $39.4M | $42.9M | $121.7M | $85.3M | — | View 990 |
| 2021 | $39.9M | $40.3M | $119.6M | $69.4M | — | View 990 |
| 2020 | $40.9M | $37.1M | $98.5M | $48.5M | — | View 990 |
| 2019 | $50.8M | $47.0M | $101.7M | $55.4M | — | View 990 |
| 2018 | $60.2M | $51.6M | $113.9M | $76.5M | — | View 990 |
| 2017 | $41.7M | $39.9M | $112.7M | $76.4M | — | — |
| 2016 | $19.7M | $17.6M | $94.5M | $62.6M | — | View 990 |
| 2015 | $16.1M | $13.7M | $80.9M | $50.5M | — | View 990 |
| 2014 | $10.8M | $9.0M | $53.8M | $25.2M | — | View 990 |
| 2013 | $9.6M | $8.6M | $47.9M | $20.9M | — | View 990 |
| 2012 | $10.5M | $10.2M | $42.2M | $17.1M | — | View 990 |
| 2011 | $16.4M | $12.5M | $39.4M | $15.1M | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $41.5M, expenses of $40.0M, and assets of $118.1M (revenue +5.4% year-over-year).
- 2022: Revenue of $39.4M, expenses of $42.9M, and assets of $121.7M (revenue -1.4% year-over-year).
- 2021: Revenue of $39.9M, expenses of $40.3M, and assets of $119.6M (revenue -2.4% year-over-year).
- 2020: Revenue of $40.9M, expenses of $37.1M, and assets of $98.5M (revenue -19.4% year-over-year).
- 2019: Revenue of $50.8M, expenses of $47.0M, and assets of $101.7M (revenue -15.6% year-over-year).
- 2018: Revenue of $60.2M, expenses of $51.6M, and assets of $113.9M (revenue +44.5% year-over-year).
- 2017: Revenue of $41.7M, expenses of $39.9M, and assets of $112.7M (revenue +111.4% year-over-year).
- 2016: Revenue of $19.7M, expenses of $17.6M, and assets of $94.5M (revenue +22.3% year-over-year).
- 2015: Revenue of $16.1M, expenses of $13.7M, and assets of $80.9M (revenue +49.7% year-over-year).
- 2014: Revenue of $10.8M, expenses of $9.0M, and assets of $53.8M (revenue +12.1% year-over-year).
- 2013: Revenue of $9.6M, expenses of $8.6M, and assets of $47.9M (revenue -8.7% year-over-year).
- 2012: Revenue of $10.5M, expenses of $10.2M, and assets of $42.2M (revenue -36.0% year-over-year).
- 2011: Revenue of $16.4M, expenses of $12.5M, and assets of $39.4M.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Alliance For Clinical Trials In Oncology Foundation:
Data Sources and Methodology
This transparency report for Alliance For Clinical Trials In Oncology Foundation is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.